Affinity maturation and characterization of the ofatumumab monoclonal antibody. Issue 1 (30th August 2018)

• Record Type: Journal Article
• Authors: Payandeh, Zahra; Rajabibazl, Masoumeh; Mortazavi, Yousef; Rahimpour, Azam; Taromchi, Amir Hossein; Dastmalchi, Siavoush
• Is Part Of: Journal of cellular biochemistry. Volume 120:Issue 1(2019)
• Page Start: 940
• Page End: 950
• Publication Date: 2018-08-30
• Subjects: affinity binding -- CD20 -- chronic lymphocytic leukemia -- monoclonal antibodies -- ofatumumab; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.27457
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: CD20 molecule, a phosphoprotein with 297 amino acids and four transmembrane domains, is a member of MS4A protein family. Anti‐CD20 antibodies such as ofatumumab, which have been developed for cancer treatment and has demonstrated efficacy in relapsed/refractory chronic lymphocytic leukemia, are among the most successful therapies to date. Rational engineering methods can be applied with reasonable success to improve functional characteristics of antibodies. Considering the importance of this issue, we have used in silico modeling approach for the improvement of ofatumumab monoclonal antibody. Four mutated variants of ofatumumab were developed and expressed in Chinese hamster ovary (CHO) cells along with the unmodified antibody. Analysis of affinity of the purified antibodies with CD20 showed significant improvement in antigen‐binding characteristics of one of the variants compared with the control antibody. This study represents the first step toward development of the second generation ofatumumab antibody with improved affinity.